MedTrace Logo

ACTolog in Patients With Solid Cancers

NCT02876510 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-02-04

No results posted yet for this study

Summary

The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.

Conditions

Interventions

DRUG

Fludarabine

Fludarabine infusion

DRUG

Cyclophosphamide

Cyclophosphamide infusion

BIOLOGICAL

IMA101 product

i.v. infusion of IMA101 product(s).

BIOLOGICAL

Recombinant human interleukin-2

Low dose IL-2 Infusion for two weeks

DIAGNOSTIC_TEST

IMADetect

IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.

DRUG

Atezolizumab

Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Immatics US, Inc.

    lead INDUSTRY

Principal Investigators

  • Cedrik Britten, M.D. · Immatics US, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2021-09-22
Completion
2021-09-22
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02876510 on ClinicalTrials.gov